CVS Health (CVS) M&A announcement summary
Event summary combining transcript, slides, and related documents.
M&A announcement summary
4 Nov, 2026Deal rationale and strategic fit
Combine local pharmacy and clinical access with Aetna’s health benefits, financing, provider collaboration and consumer engagement to make care more integrated, accessible and affordable.
Use pharmacy and medical data, predictive analytics and clinical programs across in-store, digital and home-based touchpoints to improve engagement, adherence and access to lower-cost care.
Target growth in Medicare and Medicaid, better Medicare Advantage and Part D coordination, and expanded value-based care and chronic-condition management.
Financial terms and conditions
Aetna shareholders to receive $145 cash and 0.8378 shares per share, implying ~$207 per share; transaction valued at $69B in equity and $77B including assumed debt.
At closing, existing shareholders expected to own 78% and Aetna shareholders 22%; TTM Q3 2017 pro forma revenue was $221.4B and adjusted EBITDA $18.5B.
Funding sources included $4.1B available cash, $44.8B new debt and $21.0B new equity; $49B of financing commitments, with closing not contingent on financing.
Low- to mid-single-digit accretion expected in the second full year after closing, with no meaningful impact in year one.
Pro forma leverage expected to reach ~4.6x; repurchases to pause, dividend maintained, and debt paydown targeted to bring leverage to the low-3x range longer term.
Synergies and expected cost savings
Target $750M in synergies in the second full year after closing, with greater long-term potential; near-term target primarily reflects cost and care-management savings, with virtually no revenue synergies assumed.
Near-term levers include streamlining corporate functions, improving vendor pricing, combining PBM and PDP operations, and improving enterprise dispensing.
Medical-cost opportunities include reducing overtreatment and care-delivery failures, shifting care to lower-cost sites, and using MinuteClinic and Coram assets.
Existing integrated programs cited 45% higher case-management engagement and $20 PMPM lower total medical costs; chronic-condition savings can reach $117 per member per month.
Latest events from CVS Health
- Separation aims to unlock standalone growth while preserving investment-grade balance sheets.CVS
8th Annual Wolfe Research Healthcare Conference - Care delivery expansion and post-deleveraging capital choices shape the forward strategy.CVS
30th Annual Credit Suisse Healthcare Conference - PBM cost controls, health plan growth and integrated care underpin the outlook.CVS
The 2016 Morgan Stanley Global Healthcare Conference - Integrated pharmacy scale supported growth and more than $5B in planned 2016 shareholder returns.CVS
The UBS 2016 Global Healthcare Conference - Integrated pharmacy and clinical programs aim to improve outcomes and reduce care costs.CVS
UBS Global Healthcare Conference 2017 - Signify bolsters in-home care and value-based strategy amid stable utilization.CVS
Morgan Stanley 20th Annual Global Healthcare Conference - Aetna integration targets >$750M in 2020 synergies and broader medical-cost savings.CVS
JP Morgan 37th Annual Healthcare conference - Cost savings and payer partnerships support long-term growth and shareholder returns.CVS
Investor Day 2016 - FY18 operating profit growth guided to 1%–4%, tempered by PBM and deal-related headwinds.CVS
Guidance